Health Care & Life Sciences » Biotechnology | BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
5,285.80
4,646.00
9,617.60
11,372.20
11,328.30
20,053.30
Depreciation, Depletion & Amortization
64.30
247.10
933.00
1,691.50
2,239.60
2,432.90
Other Funds
197.40
1,939.80
3,808.40
302.80
-
185.30
Funds from Operations
5,451.20
5,342.30
11,112.20
10,530.50
15,245.60
22,761.70
Changes in Working Capital
315.60
786.80
505.60
5,821.80
2,088.00
5,031.10
Net Operating Cash Flow
5,135.50
6,129.20
10,606.70
16,352.30
13,157.70
17,730.50
Capital Expenditures
600.00
-
-
-
-
Sale of Fixed Assets & Businesses
-
1.20
-
-
-
Purchase/Sale of Investments
1,847.00
5,201.40
20,109.50
16,692.50
10,366.50
Net Investing Cash Flow
2,447.00
5,200.30
20,109.50
16,692.50
10,366.50
Net Financing Cash Flow
447.50
3,257.00
4,829.90
34.40
220.70
Net Change in Cash
2,241.10
4,186.00
4,672.90
374.50
2,570.40
Free Cash Flow
5,135.60
-
10,606.70
16,352.40
13,157.70
Deferred Taxes & Investment Tax Credit
10.70
429.00
455.80
2,667.20
1,550.40
90.20
Change in Capital Stock
644.90
1,317.20
1,021.50
337.20
220.70

About BioSpecifics Technologies

View Profile
Address
35 Wilbur Street
Lynbrook New York 11563
United States
Employees -
Website http://www.biospecifics.com
Updated 07/08/2019
BioSpecifics Technologies Corp. engages in the development of an injectable collagenase for multiple indications. Its products include XIAFLEX, which is a treatment used for Dupuytren's contracture. The company was founded in 1990 and is headquartered in Lynbrook, NY.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.